z-logo
Premium
In vivo Targeting of DNA Vaccines to Dendritic Cells via the Mannose Receptor Induces Long‐Lasting Immunity against Melanoma
Author(s) -
Moku Gopikrishna,
Vangala Swathi,
Gulla Suresh Kumar,
Yakati Venu
Publication year - 2021
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.202000364
Subject(s) - mannose receptor , in vivo , mannose , cd11c , dendritic cell , immunology , melanoma , immune system , cancer research , chemistry , microbiology and biotechnology , biology , in vitro , biochemistry , macrophage , gene , phenotype
Herein, we report effective, C‐type lectin mannose receptor (MR)‐selective, in vivo dendritic cell (DC)‐targeting lipid nanoparticles (LNPs) of a novel lipid‐containing mannose‐mimicking di‐shikimoyl‐ and guanidine head group and two n ‐hexadecyl hydrophobic tails (DSG). Subcutaneous administration of LNPs of the DSG/p‐CMV‐GFP complex showed a significant expression of green fluorescence protein in the CD11c + DCs of the neighboring lymph nodes compared to the control LNPs of the BBG/p‐CMV‐GFP complex. Mannose receptor‐facilitated in vivo DC‐targeted vaccination (s.c.) with the electrostatic complex of LNPs of DSG/pCMV‐MART1 stimulated long‐lasting (270 days post B16F10 tumor challenge) antimelanoma immunity under prophylactic conditions. Remarkably, under therapeutic settings, vaccination (s.c.) with LNPs of the DSG/pCMV‐MART1 complex significantly delayed melanoma growth and improved the survival of mice with melanoma. These findings demonstrate that this nonviral delivery system offers a resilient and potential approach to deliver DNA vaccines encoding tumor antigens to DCs in vivo with high efficacy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here